ST03
Regimen
- Experimental
- perioperative ECX + bevacizumab with 6 maintenance doses
- Control
- perioperative ECX
Population
Resectable gastric, GEJ, or lower oesophageal adenocarcinoma
Key finding
3y OS 50.3% vs 48.1% (HR 1.08, 95% CI 0.91-1.29, p=0.36); anastomotic leak after oesophagogastrectomy 24% vs 10% on bev arm
Source: PMID 28163000